Year All20242023202220212020201920182017 Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference Sep 06, 2022 Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates Aug 15, 2022 Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures Jul 26, 2022 Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE) Jul 19, 2022 Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases Jun 16, 2022 Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer Jun 07, 2022 Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference Jun 01, 2022 Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights May 10, 2022 Inozyme Pharma to Present at Upcoming Investor Conferences May 03, 2022 Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market Apr 14, 2022
Year All20242023202220212020201920182017 Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference Sep 06, 2022 Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates Aug 15, 2022 Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures Jul 26, 2022 Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE) Jul 19, 2022 Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases Jun 16, 2022 Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer Jun 07, 2022 Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference Jun 01, 2022 Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights May 10, 2022 Inozyme Pharma to Present at Upcoming Investor Conferences May 03, 2022 Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market Apr 14, 2022
Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates Aug 15, 2022
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures Jul 26, 2022
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE) Jul 19, 2022
Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases Jun 16, 2022
Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights May 10, 2022